Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
Eton Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update
June 13, 2019
Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients NDA was submitted in May 2019 ; product launch anticipated in 1H 2020 Lamotrigine market currently exceeds $700 million annually DEER PARK, Ill.
Read More
Eton Pharmaceuticals to Present at 20th Annual B. Riley FBR Investor Conference
May 15, 2019
DEER PARK, Ill. , May 15, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen , Chief Executive Officer, will present at the 20 th Annual B.
Read More
Eton Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Business Progress
May 7, 2019
– Four Products Currently Under Review with the FDA –  – Expecting Multiple Product Launches in Second Half of 2019 – – Company to Host Conference Call and Webcast today at 4:30 p.m. ET ( 3:30 p.m. CT ) - DEER PARK, Ill. , May 07, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc.
Read More
Email Alerts

Eton
Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
More events are coming soon.